ADIMMUNE CORPORATION
๐น๐ผTaiwan
- Country
- ๐น๐ผTaiwan
- Ownership
- -
- Established
- 1965-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.adimmune.com.tw/
Clinical Trials
16
Active:1
Completed:15
Trial Phases
4 Phases
Phase 1:4
Phase 3:3
Phase 4:5
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)โข Click on a phase to view related trials
Phase 4
5 (33.3%)Phase 1
4 (26.7%)Not Applicable
3 (20.0%)Phase 3
3 (20.0%)Dose-finding Study for AdimrSC-2f Vaccine
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 241
- Registration Number
- NCT05104489
- Locations
- ๐ฎ๐ฉ
University Gadjah Mada Academic Hospital, Yogyakarta, Indonesia
A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT04522089
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 174
- Registration Number
- NCT04101435
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT01759654
- Locations
- ๐จ๐ณ
National Taiwan University Hospital, Taipei, Taiwan
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
Phase 3
Completed
- Conditions
- Influenza
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2018-07-16
- Lead Sponsor
- Adimmune Corporation
- Target Recruit Count
- 122
- Registration Number
- NCT01755364
- Locations
- ๐จ๐ณ
Chang Gung Memorial Hospital at Linkuo, Taoyuan, Taiwan
- Prev
- 1
- 2
- 3
- Next
News
No news found